Is magnesium sulphate a safe and effective treatment option for adult patients presenting with atrial fibrillation to the department ofEmergency medicine?
Phase 4
- Conditions
- Health Condition 1: I48- Atrial fibrillation and flutter
- Registration Number
- CTRI/2023/05/052653
- Lead Sponsor
- Fluid research fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. New onset atrial fibrillation with fast ventricular rate
2. Persistent atrial fibrillation with fast ventricular rate
Exclusion Criteria
1. Patients already on calcium channel blockers
2. Indication for electrical cardioversion
3. Known case of heart blocks
4. Known Severe hypomagnesemia or hypermagnesemia (serum Magnesium levels < 1.2 mg/dl or > 5.0mg/dl)
5. Known case of Renal failure with recent creatinine > 3.0 mg/dl
6. Systolic Blood pressure < 90mmhg
7. Altered mental status
8. Wide complex ventricular response
9. Acute myocardial infarction
10. Cardiogenic shock
11. Other arrhythmias
12. Pregnant patients
13. Acute pulmonary edema with SPO2 < 90%, PO2 < 60 mmHg
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To reduce the ventricular rate to less than 100/min or reduction by 20% of the initial heart rate.Timepoint: 30 minutes after drug administration
- Secondary Outcome Measures
Name Time Method umber of drugs required for rate control apart from the study drug. <br/ ><br>Timepoint: After 6 hours;Number of patients in sinus rhythmTimepoint: After 48 hours;Outcome of the patients: <br/ ><br>a.Discharge from ED <br/ ><br>b.Admission to ICU or ward <br/ ><br>c.Discharged against medical advice <br/ ><br>Timepoint: After 6 hours;Percentage of cases reverting back to sinus rhythm. <br/ ><br>Timepoint: After 6 hours;Resolution time: time taken for the desired effect to occur after initiating the primary drugTimepoint: After 6 hours;To assess the complications associated with use of MgSo4 and diltiazem. Incidence of hypotension, bradycardia, respiratory depression. <br/ ><br>Timepoint: After 6 hours